Literature DB >> 35139159

Heart failure with preserved ejection fraction in patients with normal natriuretic peptide levels is associated with increased morbidity and mortality.

Frederik H Verbrugge1,2,3, Kazunori Omote1, Yogesh N V Reddy1, Hidemi Sorimachi1, Masaru Obokata1, Barry A Borlaug1.   

Abstract

BACKGROUND: A substantial proportion of patients with heart failure (HF) with preserved ejection fraction (HFpEF) present with normal natriuretic peptide (NP) levels. The pathophysiology and natural history for this phenotype remain unclear. METHODS AND
RESULTS: Consecutive subjects undergoing invasive cardiopulmonary exercise testing for unexplained dyspnoea at Mayo Clinic in 2006-18 were studied. Heart failure with preserved ejection fraction was defined as a pulmonary arterial wedge pressure (PAWP) ≥15 mmHg (rest) or ≥25 mmHg (exercise). Patients with HFpEF and normal NP [N-terminal of the pro-hormone B-type natriuretic peptide (NT-proBNP) < 125 ng/L] were compared with HFpEF with high NP (NT-proBNP ≥ 125 ng/L) and controls with normal haemodynamics. Patients with HFpEF and normal (n = 157) vs. high NP (n = 263) were younger, yet older than controls (n = 161), with an intermediate comorbidity profile. Normal NP HFpEF was associated with more left ventricular hypertrophy and worse diastolic function compared with controls, but better diastolic function, lower left atrial volumes, superior right ventricular function, and less mitral/tricuspid regurgitation compared with high NP HFpEF. Cardiac output (CO) reserve with exercise was preserved in normal NP HFpEF [101% predicted, interquartile range (IQR): 75-124%], but this was achieved only at the cost of higher left ventricular transmural pressure (LVTMP) (14 ± 6 mmHg vs. 7 ± 4 mmHg in controls, P < 0.001). In contrast, CO reserve was decreased in high NP HFpEF (85% predicted, IQR: 59-109%), with lower LVTMP (10 ± 8 mmHg) compared with normal NP HFpEF (P < 0.001), despite similar PAWP. Patients with high NP HFpEF displayed the highest event rates, but normal NP HFpEF still had 2.7-fold higher risk for mortality or HF readmissions compared with controls (hazard ratio: 2.74, 95% confidence interval: 1.02-7.32) after adjusting for age, sex, and body mass index.
CONCLUSION: Patients with HFpEF and normal NP display mild diastolic dysfunction and preserved CO reserve during exercise, despite marked elevation in filling pressures. While clinical outcomes are not as poor compared with patients with high NP, patients with normal NP HFpEF exhibit increased risk of death or HF readmissions compared with patients without HF, emphasizing the importance of this phenotype.
© The Author(s) 2022. Published by Oxford University Press on behalf of European Society of Cardiology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  Diastolic heart failure; Exercise tolerance; Mortality; Natriuretic peptides; Obesity

Mesh:

Substances:

Year:  2022        PMID: 35139159     DOI: 10.1093/eurheartj/ehab911

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   35.855


  5 in total

1.  Longitudinal Evolution of Cardiac Dysfunction in Heart Failure and Preserved Ejection Fraction With Normal Natriuretic Peptide Levels.

Authors:  Hidemi Sorimachi; Frederik H Verbrugge; Kazunori Omote; Massar Omar; Masaru Obokata; Yogesh N V Reddy; Zi Ye; Hector I Michelena; Barry A Borlaug
Journal:  Circulation       Date:  2022-08-08       Impact factor: 39.918

2.  Sex-specific responses to slow progressive pressure overload in a large animal model of HFpEF.

Authors:  Deborah M Eaton; Remus M Berretta; Jacqueline E Lynch; Joshua G Travers; Ryan D Pfeiffer; Michelle L Hulke; Huaqing Zhao; Alexander R H Hobby; Giana Schena; Jaslyn P Johnson; Markus Wallner; Edward Lau; Maggie P Y Lam; Kathleen C Woulfe; Nathan R Tucker; Timothy A McKinsey; Marla R Wolfson; Steven R Houser
Journal:  Am J Physiol Heart Circ Physiol       Date:  2022-09-02       Impact factor: 5.125

3.  Diagnostic and prognostic value of serum soluble suppression of tumorigenicity-2 in heart failure with preserved ejection fraction: A systematic review and meta-analysis.

Authors:  Yujiao Shi; Jiangang Liu; Chunqiu Liu; Xiong Shuang; Chenguang Yang; Wenbo Qiao; Guoju Dong
Journal:  Front Cardiovasc Med       Date:  2022-09-20

4.  Exercise testing in heart failure with preserved ejection fraction: an appraisal through diagnosis, pathophysiology and therapy - A clinical consensus statement of the Heart Failure Association and European Association of Preventive Cardiology of the European Society of Cardiology.

Authors:  Marco Guazzi; Matthias Wilhelm; Martin Halle; Emeline Van Craenenbroeck; Hareld Kemps; Rudolph A de Boer; Andrew J S Coats; Lars Lund; Donna Mancini; Barry Borlaug; Gerasimos Filippatos; Burkert Pieske
Journal:  Eur J Heart Fail       Date:  2022-07-31       Impact factor: 17.349

Review 5.  Exercise Stress Echocardiography in the Diagnostic Evaluation of Heart Failure with Preserved Ejection Fraction.

Authors:  Tomonari Harada; Kazuki Kagami; Toshimitsu Kato; Hideki Ishii; Masaru Obokata
Journal:  J Cardiovasc Dev Dis       Date:  2022-03-17
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.